General Information of Drug (ID: DMG1U5K)

Drug Name
Rocatinlimab Drug Info
Synonyms AMG 451 / KHK4083
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMG1U5K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting OX40L receptor (CD134)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GBR 830 DM2VO9T Atopic dermatitis EA80 Phase 2 [3]
PF-04518600 DMZMUIL Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
INCAGN01949 DMK7OHI Advanced malignancy 2A00-2F9Z Phase 2 [5]
INCAGN1949 DM7OE3X Solid tumour/cancer 2A00-2F9Z Phase 1/2 [6]
TAK-252 DM1AKNI Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Anti-OX40 mab DMFZ52G Prostate cancer 2C82.0 Phase 1 [8]
MEDI0562 DMYVBU6 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
BGB-A445 DMQMEDH Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
YH002 DMWVRHD Aggressive cancer 2A00-2F9Z Phase 1 [10]
YH006 DMRECC2 Aggressive cancer 2A00-2F9Z Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
OX40L receptor (CD134) TTL31H0 TNR4_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05633355) A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged >= 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit). U.S.National Institutes of Health.
2 An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-214.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of Shattuck Labs.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
9 Clinical pipeline report, company report or official report of BeiGene.
10 Clinical pipeline report, company report or official report of Biocytogen
11 Clinical pipeline report, company report or official report of Biocytogen